GANYMED Pharmaceuticals AG

GANYMED Pharmaceuticals AG is developing monoclonal antibody therapeutics against solid tumors, where current therapies are poor and where there is an overriding medical need. The therapeutic efficacy of current solid cancer therapeutics is severely limited, because their molecular targets are elevated in a subset of a particular cancer but they are also found widely in normal tissues. In contrast, GANYMED's pan cancer surface antigens are uniquely specific for cancer tissues and can be expected to show greater therapeutic efficacy and better safety allowing significant reduction in time to market. GANYMED will market its

Contact Details: Freiligrathstrasse 12 Mainz D-55131 Germany Tel: 49 (0)6131 / 1440 - 100 Fax: 49 (0)6131 / 1440 - 111 Email: info@ganymed-pharmaceuticals.com WWW: www.ganymed-pharmaceuticals.com/

Recent Publications by GANYMED Pharmaceuticals AG:
In silico strategy for detection of target candidates for antibody therapy of solid tumors. In contrast to earlier attempts for the identification of target...	2nd July, 2008	Ganymed Pharmaceuticals AG, Mainz, Germany.	Gene. 2008 May 15;414(1-2):76-84. Epub 2008 Feb 19. DOI Direct Link

Press Releases on GANYMED Pharmaceuticals AG:
GANYMED names Rainer Wessel Ph.D. as President & CEO	1st December, 2003	Ganymed	GANYMED names Rainer Wessel Ph.D. as President & CEO Mainz, Germany (April 1, 2004) - GANYMED Pharmaceuticals AG, an independent biotechnology company with an initial focus on cancer,
GANYMED Pharmaceuticals AG and the University of Rotterdam Establish new	1st January, 1970	Ganymed	GANYMED Pharmaceuticals AG and the University of Rotterdam Establish new Cooperation New Cooperation on Identification of Multiple Sclerosis Pathogens Established Between GANYMED
Ganymed Announces License Of Wt1 Immunotherapy Rights By Corixa And Kirin	1st January, 1970	Ganymed	Ganymed Announces License Of Wt1 Immunotherapy Rights By Corixa And Kirin Mainz, Germany (June 08, 2004) - Ganymed Pharmaceuticals AG, Mainz, Germany, announced today that Corixa Corporation

GANYMED Pharmaceuticals AG Clinical Trials:
Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

GANYMED Pharmaceuticals AG Patents:
US Patent No.	Title
7527933	Genetic products differentially expressed in tumors and the use thereof
7429461	Genetic products differentially expressed in tumors and use thereof
7326767	Immunotherapeutic methods using epitopes of WT-1 and GATA-1

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 405 times since April 2007, the link to the organisation's website has been followed 64 times

Recent Search Terms used to find this page: Mainz GANYMED Press 2009 | Presse ganymed Pharmaceuticals 2009 | Ganymed Pharmaceuticals | Ganymed Pharmaceuticals | gany | Ganymed Pharmaceuticals AG | .

Search for more companies in Mainz

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for GANYMED Pharmaceuticals AG